Background House Dust Mite (HDM) is the most common indoor allergen triggering allergic symptoms. First-line pharmacotherapy treatment recommended in international guidelines, while avoidance of allergens represents a still unmet guideline principle. AM-301 new non-pharmacological nasal spray that creates protective gel-like barrier on mucosa, preventing contact with allergens. Methods This ran...

The role of nasal endoscopy in the prescription of allergen immunotherapy Key words Allergic rhinitis, allergen immunotherapy, nasal endoscopy. According to the more recent guidelines, allergen specific immunotherapy (SIT), can be prescribed in rhinocon-junctivitis and/or asthma, if an IgE mediated mechanism is well ascertained, if the causal role of a given allergen is uncontrovertibly demonst...

Allergy to house dust mite is one of the most common causes of allergic rhinitis. A novel tyrosine-adsorbed, modified allergen product, Acarovac Plus, developed for the treatment of perennial mite allergy seeks to address the underlying cause of allergic rhinitis in this instance. One of two dosing regimens may be used, either the Conventional Regimen or the Cluster Regimen. We sought to compar...

RHINITIS IS A GLOBAL PROBLEM AND IS DEFINED AS THE PRESENCE OF AT LEAST ONE OF THE FOLLOWING: congestion, rhinorrhea, sneezing, nasal itching, and nasal obstruction. The two major classifications are allergic and nonallergic rhinitis (NAR). Allergic rhinitis occurs when an allergen is the trigger for the nasal symptoms. NAR is when obstruction and rhinorrhea occurs in relation to nonallergic, n...

Selecting an appropriate allergen-specific immunotherapy (AIT) regimen for polysensitised allergic rhinitis (AR) patients is challenging clinicians. Although previous studies showed comparable effectiveness of single-allergen AIT with house dust mite (HDM) extract between monosensitised and AR patients, there no systematic review meta-analysis demonstrating the HDM AIT. In this meta-analysis, w...

Repeated low-dose allergen challenge increases airway hyperresponsiveness in atopic asthmatics. However, it is not known whether low-dose allergen challenge increases airway inflammation. Eight atopic asthmatics were enrolled in a controlled, cross-over study to evaluate the effect and time course of repeated low-dose allergen challenge on airway inflammation and hyperresponsiveness. The dose o...

BACKGROUND Airway wall remodelling and inflammation are features of chronic asthma. Transforming growth factor beta (TGF-beta) has been implicated in these processes. AIM To determine the effect of allergen challenge on airway inflammation and remodelling and whether TGF-beta isoforms and the Smad signalling pathways are involved. METHODS Thirteen patients with atopic asthma underwent inhal...